Preeclampsia Diagnostics Market Expected to Reach USD 2.3 Billion by 2031 Amid Rising Global Pregnancy Complications

The global preeclampsia diagnostics market is witnessing steady growth due to the rising prevalence of pregnancy-related complications and increasing awareness about maternal health. Preeclampsia is a pregnancy-specific disorder characterized by high blood pressure and the presence of protein in urine after the 20th week of pregnancy. If left untreated, it can lead to severe complications for both mother and baby.

According to recent industry analysis, the global preeclampsia diagnostics market was valued at US$ 1.5 Bn in 2021 and is projected to reach US$ 2.3 Bn by 2031, expanding at a CAGR of 3.8% during the forecast period (2022-2031). The market is benefiting from the growing demand for early detection technologies, improvements in healthcare infrastructure, and increased investments in maternal health research.

Preeclampsia affects 2% to 8% of pregnancies worldwide, making early diagnosis critical for preventing complications such as eclampsia, kidney failure, liver damage, and blood clotting disorders. As awareness of maternal health risks continues to grow, healthcare providers and governments are increasingly focusing on improving screening and diagnostic capabilities.

Access important conclusions and data points from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32423

Key Drivers of Market Growth

Rising Global Prevalence of Preeclampsia
One of the major factors driving the growth of the preeclampsia diagnostics market is the rising incidence of pregnancy-related hypertension disorders. Lifestyle changes, poor dietary habits, lack of physical activity, increasing obesity rates, and delayed pregnancies have contributed to higher cases of preeclampsia globally.
In the United States, studies indicate a noticeable increase in the number of preeclampsia cases in recent years. Factors such as advanced maternal age, diabetes, and obesity have significantly raised the risk of the disorder among pregnant women.
Healthcare authorities have also reported that preeclampsia remains a leading cause of maternal mortality and complications during childbirth. As a result, healthcare systems worldwide are prioritizing early detection and monitoring to reduce maternal health risks.

Increasing Awareness and Screening Programs
Growing awareness campaigns and government initiatives focused on maternal healthcare have significantly increased the demand for diagnostic testing. Hospitals and healthcare institutions are implementing routine screening protocols to identify high-risk pregnancies early.
Healthcare providers are also encouraging regular prenatal monitoring, which includes blood pressure checks, urine tests, and biochemical screening tests. These efforts are expected to strengthen the adoption of preeclampsia diagnostic tools across healthcare facilities.

Rising Funding for Maternal Health Research
Another key driver of market growth is the increase in funding from governments, healthcare organizations, and foundations dedicated to maternal health research. Various initiatives are supporting the development of innovative diagnostic solutions to detect preeclampsia earlier and more accurately.
Organizations such as the Preeclampsia Foundation are actively supporting research programs and providing grants to improve diagnostic technologies. In addition, the global maternal health initiative Merck for Mothers is funding projects aimed at reducing maternal mortality and improving pregnancy outcomes.
These investments are expected to accelerate the development of advanced diagnostic tests and expand access to screening in developing regions.

Market Trends & Innovations

Increasing Preference for Blood-Based Diagnostic Tests
Blood-based diagnostic tests have emerged as one of the most reliable methods for detecting preeclampsia. In 2021, the blood test segment accounted for more than 55% of the global market share due to its high accuracy and ability to detect biomarkers associated with the disorder.
Biochemical screening methods help identify preeclampsia during the first trimester as well as later stages of pregnancy. Early diagnosis enables healthcare providers to closely monitor patients and manage complications effectively.

Growth in Advanced Biomarker Testing
Technological innovations are enabling the development of biomarker-based diagnostic tools capable of identifying early signs of preeclampsia. Biomarkers such as placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are increasingly used in advanced diagnostic tests.
Diagnostic companies are focusing on integrating these biomarkers into laboratory platforms to provide more precise and reliable screening methods.

Key Players and Industry Leaders

The global preeclampsia diagnostics market is moderately consolidated, with a few major companies accounting for a significant share of the market. These companies are heavily investing in research and development to expand their product portfolios and strengthen their global presence.
Prominent players operating in the market include:

• Abbott Laboratories
• ACON Laboratories, Inc.
• ARKRAY, Inc.
• Bio-Rad Laboratories, Inc.
• Cardinal Health
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Sera Prognostics
• Metabolomic Diagnostics Ltd.
These companies are focusing on strategic collaborations, acquisitions, and technological advancements to improve diagnostic capabilities and expand their global market share.

Recent Developments

The preeclampsia diagnostics industry has witnessed several important developments in recent years aimed at improving early detection and diagnosis.
• In July 2022, PerkinElmer, Inc. announced that its DELFIA Xpress PlGF 1-2-3TM kit and sFlt-1/PlGF ratio test were included in updated diagnostic guidance issued by the National Institute for Health and Care Excellence in the United Kingdom for diagnosing suspected preterm preeclampsia.

• In February 2020, Shuwen Biotech Co. Ltd. partnered with PerkinElmer, Inc. to distribute innovative diagnostic tests for preeclampsia in over 100 countries worldwide.

• In May 2019, the International Federation of Gynecology and Obstetrics introduced new global guidelines recommending first-trimester screening for preeclampsia.

• In September 2017, Siemens Healthineers AG received CE Mark certification for its Atellica Solution diagnostic platform designed to support advanced laboratory testing procedures.

These developments highlight the growing focus on improving diagnostic technologies and strengthening early detection capabilities.

New Opportunities and Challenges

Opportunities
Several emerging opportunities are expected to drive the growth of the preeclampsia diagnostics market in the coming years:
• Increasing adoption of prenatal screening programs
• Growth in point-of-care diagnostic technologies
• Expansion of healthcare infrastructure in developing countries
• Rising awareness of maternal health and pregnancy complications
Developing countries are expected to present significant growth opportunities as governments invest in improving maternal healthcare services.

Challenges
Despite promising growth prospects, the market faces certain challenges:
• Limited access to advanced diagnostic technologies in rural areas
• High cost of specialized testing procedures
• Lack of awareness about early screening in low-income regions
Addressing these challenges will require increased investment in healthcare infrastructure and educational initiatives to improve maternal health awareness.

Buy this Premium Research Report to gain valuable industry intelligence - https://www.transparencymarketresearch.com/checkout.php?rep_id=32423<ype=S

Market Segmentation

The preeclampsia diagnostics market can be segmented based on test type, product & services, end-user, and region.

By Test Type
• Blood Test
• Urine Test
• Others

By Product & Services
• Instruments
• Reagents & Consumables
• Services

By End-user
• Hospitals
• Diagnostic Centers
• Others

Among these segments, hospitals accounted for the largest share in 2021 due to the high number of patients seeking diagnosis and treatment in hospital settings.

Regional Insights

North America
North America held the largest market share of approximately 35% in 2021. The region benefits from advanced healthcare infrastructure, high awareness levels, and strong investments in research and development.
Healthcare organizations in the United States and Canada are actively working on improving maternal health screening programs, which is expected to drive market growth in the region.

Asia Pacific
Asia Pacific is projected to be the fastest-growing regional market during the forecast period. The growth is driven by increasing population levels, rising healthcare awareness, and improvements in healthcare infrastructure across countries such as China and India.
Governments in the region are also implementing maternal health initiatives aimed at reducing pregnancy-related complications.

Key Trends for the Future

Several trends are expected to shape the future of the preeclampsia diagnostics market:
• Growing adoption of biomarker-based diagnostic testing
• Integration of AI and digital healthcare technologies in prenatal monitoring
• Increased focus on early pregnancy screening programs
• Rising demand for non-invasive diagnostic solutions
These trends are expected to significantly enhance early detection and improve pregnancy outcomes worldwide.

Future Outlook

The future of the preeclampsia diagnostics market looks promising as healthcare systems around the world increasingly prioritize maternal health. Continuous technological advancements, rising healthcare investments, and growing awareness about pregnancy complications are expected to drive steady market growth.
By 2031, the market is projected to reach US$ 2.3 Bn, supported by improvements in diagnostic accuracy and expanded screening programs across both developed and developing regions.
As healthcare providers continue to adopt innovative diagnostic technologies, early detection of preeclampsia will become more accessible, helping reduce maternal mortality rates and improve pregnancy outcomes globally.

Important FAQs

How big was the global preeclampsia diagnostics market in 2021?
The market was valued at US$ 1.5 Bn in 2021.

What is the expected growth rate of the market?
The global preeclampsia diagnostics market is expected to grow at a CAGR of 3.8% from 2022 to 2031.

What will be the market size by 2031?
The market is projected to reach US$ 2.3 Bn by the end of 2031.

Which test type dominates the market?
Blood tests dominated the market in 2021, accounting for more than 55% share.

Which region holds the largest market share?
North America accounted for the largest share of the global market in 2021.

Who are the major players in the market?
Key companies include Abbott Laboratories, ACON Laboratories, ARKRAY, Bio-Rad Laboratories, Cardinal Health, Danaher Corporation, F. Hoffmann-La Roche, Sera Prognostics, Metabolomic Diagnostics, and Siemens Healthineers.

More Related Reports-

PCR & Real-time PCR Molecular Diagnostics Market: https://www.transparencymarketresearch.com/pcr-realtime-pcr-molecular-diagnostics-market.html

Cell Free RNA Diagnostics Market: https://www.transparencymarketresearch.com/cell-free-rna-diagnostics-market.html

Antibody Specificity Testing Market: https://www.transparencymarketresearch.com/antibody-specificity-testing-market.html

Gene Fusion Testing Market: https://www.transparencymarketresearch.com/gene-fusion-testing-market.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.